Research progress of antibody–drug conjugates in gynecologic cancer
Abstract Gynecologic cancer is a critical concern in the field of women’s health, and traditional treatment methods have demonstrated limited efficacy for certain advanced and recurrent gynecologic cancers. In recent years, antibody–drug conjugate (ADC) therapy, as an emerging targeted approach, has gained increasing attention as a research hotspot. This review aims to elucidate the structure and mechanism of ADC drugs and explore their application and clinical research progress in gynecologic cancers such as ovarian cancer, cervical cancer, and endometrial cancer.
Authors
- Zhe‐Sheng Chen (ORCID: https://orcid.org/0000-0002-8289-097X)
- Dongdong Xu (ORCID: https://orcid.org/0009-0008-3411-7924)
- Zhongqiu Lin (ORCID: https://orcid.org/0000-0002-3202-5072)
- Huaiwu Lu (ORCID: https://orcid.org/0000-0002-7668-3333)
- Xuanwei Peng
Institutions
- St. John's University (US)
- Sun Yat-sen University (CN)
- Sun Yat-sen Memorial Hospital (CN)
Publication Details
- Journal
- Holistic Integrative Oncology
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1007/s44178-024-00114-8
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Beijing Xisike Clinical Oncology Research Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province